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ABSTRACT 26 
 27 
Fungi from more than one hundred genera have been implicated in subcutaneous fungal 28 
infections, usually following traumatic inoculation of the etiologic agent.  With the advent of 29 
molecular approaches to fungal identification and taxonomy, novel agents of subcutaneous 30 
mycoses are increasingly reported. In this manner, Roussoella percutanea, a novel species in 31 
Pleosporales, was described in 2014 from a subcutaneous mass in an immunocompetent male 32 
adult. A second case was discovered after analysis of historical culture collection isolates, 33 
from a pedal mass in a renal transplant patient. Here we describe a new case of subcutaneous 34 
R. percutanea infection, causing a mycotic cyst in a renal transplant patient. Although fungal 35 
infection was confirmed histologically, viable fungal isolates could not be recovered in 36 
culture from biopsy material and identification of the causative agent relied upon PCR 37 
amplification and sequencing of fungal rDNA genes. This is only the third reported case of 38 
human infection with R. percutanea worldwide, the second in a renal transplant patient, and 39 
the first from a patient resident in the UK. The current case illustrates the importance of 40 
molecular approaches for the identification of emerging fungal pathogens in culture-negative 41 
subcutaneous fungal infections. 42 
 43 
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 46 
Introduction 47 
Subcutaneous fungal infections usually occur following traumatic inoculation of the 48 
etiological agent into cutaneous or subcutaneous tissue. Although infections typically remain 49 
localised in immunocompetent individuals, without treatment they frequently become 50 
chronic, with gradual expansion to involve adjacent tissues and even bone (1-3). This 51 
heterogeneous disease spectrum includes hyalohyphomycoses (infection by fungi with 52 
hyaline hyphae), phaeohyphomycoses (infection with melanised, dematiaceous fungi), 53 
chromoblastomycoses (characterised by formation of sclerotic bodies in tissue) and 54 
eumycetoma (characterised by extensive tumefaction with formation of purosanguinous 55 
sinuses extruding fungal grains) (2-5).  56 
Fungi from more than 100 genera have been reported from subcutaneous mycoses in 57 
humans, with novel species and genera described almost weekly (5). In some cases, the 58 
responsible fungi have only been reported from individual, isolated case reports suggesting 59 
that they are infrequent agents of subcutaneous infection (6-9). For many other species, they 60 
have been predominantly associated specifically with precise clinical presentations and have 61 
been rarely or never isolated from nature (2, 4, 5, 10-12). Although certain species are 62 
predominantly associated with a specific clinical presentation, clinical picture is also 63 
determined by host immune status, with the result that accurate definition of disease entity 64 
may be difficult (13, 14). In addition, many of the agents of subcutaneous mycoses exhibit 65 
reluctant conidiation in culture, especially when isolated from chronic cases (5, 10, 12, 14). 66 
Since accurate identification of the causative agent is paramount in directing appropriate 67 
therapeutic interventions, molecular approaches using PCR amplification and sequencing of 68 
conserved regions of fungal genomic DNA is increasingly employed (14-17). Using such 69 
approaches, Roussoella percutanea, a novel species in Pleosporales, was recently described 70 
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from a subcutaneous mass in an immunocompetent male adult (18). Clinical presentation 71 
included hyphal masses with granulation tissue and fibrosis, but draining sinuses typical of 72 
eumycetoma were absent. A retrospective analysis of other culture collection isolates 73 
revealed one further historical isolate of R. percutanea, from a pedal mass in a renal 74 
transplant patient who also presented with necrosis and inflammation but without draining 75 
sinuses or fungal grains (13,18). In both cases, conidiation in culture was delayed or absent, 76 
and variable antifungal susceptibility profiles were reported for the two previous isolates 77 
(18). 78 
Here we present the first case of R. percutanea infection from the UK, involving a 79 
subcutaneous cyst from a renal transplant patient. Attempts to culture the organism from cyst 80 
tissue were unsuccessful and diagnosis and identification were achieved by PCR 81 
amplification and sequencing of fungal genomic DNA from biopsy material. 82 
 83 
Case History 84 
A 47 year old male, originally from Surat, Gujarat, but residing in the UK since 1997, 85 
underwent a renal transplant in November 2015 for end-stage renal failure of unknown cause. 86 
Post-operatively he was immune-suppressed with oral prednisolone 12.5mg once a day and 87 
tacrolimus 5mg twice daily and commenced prophylactic oral co-trimoxazole and aciclovir. 88 
Other past medical history included gout, osteoarthritis, an inguinal hernia and migraines. 89 
Post-transplant he suffered from an episode of declining renal function secondary to 90 
borderline T-cell mediated rejection, requiring two rounds of pulsed methylprednisolone and 91 
addition of mycophenylate mofetil 500mg twice daily to his immunosuppressive regimen 92 
from January 2016. His clinical course was also complicated by multiple episodes of 93 
urosepsis, including one episode of bacteraemia, due to an extended-spectrum β-lactamase 94 
producing Klebsiella pneumoniae, between January and May 2016. 95 
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During admission for an episode of Klebsiella urosepsis in March 2016 an incidental 96 
finding was made of a mobile, soft tissue mass over the right Achilles tendon. The lesion was 97 
non-tender and not adherent to the tendon itself with no masses elsewhere or evidence of 98 
lymphatic involvement or sinus tract formation. The patient had been unaware of the lesion 99 
and it had not caused him any pain or symptoms. Clinical suspicion of mycetoma was raised. 100 
Further travel history included trips to Dubai 2005 and Morocco in 2014. The patient could 101 
not re-call any specific injuries or possible inoculation events. 102 
  An ultra-sound scan confirmed a 2 by 1.5 centimetre heterogeneous nodule overlying 103 
but separate from the Achilles tendon. A biopsy of the lesion was performed which did not 104 
reveal any organisms on Gram stain and there was no growth by conventional bacterial 105 
culture (including Sabouraud’s dextrose agar). Histology revealed a diffuse macrophage 106 
infiltrate with cytoplasmic inclusions and fungal hyphae were seen on Periodic acid-Schiff 107 
and Periodic acid-Schiff-diastase stains. Empirical antifungal treatment was not started at this 108 
point due to the patient’s stable clinical condition.  109 
Microscopic analysis of biopsy material by potassium hydroxide digestion with 110 
Calcofluor enhancer (Bactidrop, Remel) revealed the presence of moderate amounts of 111 
filamentous fungal elements. These were generally amorphous, and included fine, regularly 112 
septate and acutely branching hyphae, which were hyaline to light brown together with more 113 
common short chains of swollen cells and chlamydospores. Despite prolonged culture on  a 114 
variety of mycological media, no viable fungal isolate could be recovered for further 115 
analyses. Small sections of biopsy tissue were subjected to digestion and Qiagen column 116 
purification (Qiagen Mini Blood kit) and PCR amplification of the 28S rDNA and Internal 117 
transcribed spacer 1 (ITS1) regions of the resulting extracted fungal genomic DNA using the 118 
PCR primers and conditions described previously (12, 14, 17). The sequences of the resulting 119 
PCR amplicons were 100% identical to those of the type species of Roussoella percutanea 120 
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(isolate CBS128203; GenBank accession numbers KF366448 and KF322117) present in the 121 
public synchronised databases. Treatment with oral voriconazole 200mg twice a day was then 122 
immediately commenced and total excision of the lesion took place with 5mm margins. 123 
Histology of the excised lesions confirmed fungal hyphae on both Hematoxylin/Eosin and 124 
Grocott stains. Unfortunately, due to clinical concern regarding potential interactions between 125 
voriconazole and tacrolimus, and a falling neutrophil count (to a trough of 2.1x109/litre) 126 
whilst being treated with voriconazole, anti-fungal treatment was discontinued after only 2 127 
weeks. Despite this, the patient’s wound is healing and dry at 6 weeks post-excision with no 128 
evidence of recurrence so far. 129 
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Discussion 131 
We report here the first known UK case of subcutaneous infection by R. percutanea. 132 
To our knowledge, this is only the third case reported worldwide, and the second to have 133 
affected a renal transplant patient (13,18). In all three cases, presentation differed from that 134 
seen with eumycetoma due to the presence only of inflammatory infiltrates and discrete 135 
fungal elements and absence of fungal grains or draining sinuses, Subcutaneous mycoses in 136 
immunocompetent patients frequently present diagnostic challenges due to the heterogeneous 137 
nature of clinical presentations and the fact that clinically detectable infections can take years 138 
to develop. This situation is further compounded in transplant patients, where relatively 139 
dormant fungi that have been harboured subcutaneously for many years or decades become 140 
clinically active after immunosuppression. Although most subcutaneous mycoses are thought 141 
to result from traumatic inoculation, it is hardly surprising given this protracted and variable 142 
incubation period that most patients are unable to recall any history of injury at the affected 143 
sites. This was the case with the current patient and with the two previous reports of R. 144 
percutanea subcutaneous mycoses published to date (13, 18).  145 
Previous reports have suggested strain-specific variations in antifungal susceptibility 146 
in R. percutanea (18), indicating that specific testing of patient isolates should be used to 147 
guide antifungal therapeutic decisions. Since the current case was culture-recalcitrant and no 148 
isolate was available for testing, the patients was treated with total excision of the lesion and 149 
commenced on voriconazole therapy. Unfortunately, antifungal therapy was stopped after 150 
only 2 weeks due to drug interactions. Although the patient is currently well, close follow up 151 
will be required, especially in the light of the reports of recurrences in both previous cases of 152 
R. percutanea (13,18). Finally, the current case further highlights the utility of molecular 153 
diagnostic and identification approaches in medical mycology, especially in cases of 154 
subcutaneous fungal infections where conventional identification approaches are hindered by 155 
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difficulties in recovering viable fungi from biopsy samples and organisms that fail to produce 156 
distinctive features in culture. 157 
 158 
  159 
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 214 
 215 
Figure Legend. 216 
Figure 1. Histopathological appearance of biopsy material excised from the subcutaneous 217 
cyst. H&E stain. Panel B is a magnification of a section of panel A. Scale Bars = 5 m. 218 
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